Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q1 FY2025 Earnings Presentation
30 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, August 2024
Slide 1: IOL Chemicals and Pharmaceuticals Limited Q1 FY2025 Investor Presentation
IOL Chemicals and Pharmaceuticals Limited Q1 FY2025 Investor Presentation August 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by IOL Chemicals and Pharmaceuticals Limited solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any
Slide 3: Table of Contents
Table of Contents 01 IOLCP at a glance 02 Financial Highlights 03 Company Overview Standalone Quarterly Income Statement The Journey About IOL Chemicals and Pharmaceuticals Ltd. Standalone Income - Sustained revenue Core management team Q1 FY2025 Performance Standalone Balance Sheet - Building Asset
Slide 4: IOL Chemicals & Pharma - Overview
IOL Chemicals & Pharma - Overview Incorporated in 1986, IOLCP is one of the leading API Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Team size of 2750+ employees Credit Rating: A+, outlook; stable (Care Ratings Limited) Debt free
Slide 5: Q1FY25 Performance
Q1FY25 Performance Operational Highlights Q1FY25 Financial Performance • EDQM issued CEP Certificate for Gabapentin, Allopurinol, Pantoprazole Sodium Sesquihydrate” for 509.76 58.18 11.41% alternative process (Process - II),and Valsartan, Revenues (Rs. cr) EBITDA (Rs. cr) EBITDA Margin enabling to e
Slide 6: Geographical and Segmental highlights
Geographical and Segmental highlights Chemical Segment (₹ crore) Pharma Segment (₹ crore) 233 12 400 60 214 211 207 349 10 206 332 200 296 287 295 300 50 50 8 40 150 39 200 35 100 35 4 20 2 100 50 1 0 3 0 1 0 0 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Revenue (net of Int
Slide 7: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 8: Standalone Quarterly Income Statement
Standalone Quarterly Income Statement Particulars (₹ Cr) Q1 FY25 Q1 FY24 YoY Q4 FY24 QoQ Revenues 502.4 563.2 -10.8% 503.9 -0.3% Other Income 7.4 7.1 7.5 Total Income 509.8 570.3 -10.6% 511.4 -0.3% Total Expenses 451.6 490.4 453.8 EBITDA 58.2 79.9 -27.2% 57.6 1.0% EBITDA Margin (%) 11.4% 14.0% -260
Slide 9: Standalone Income - Sustained revenue
Standalone Income - Sustained revenue Particulars (₹ Cr) FY19 FY20 FY21 FY22 FY23 FY24 Revenues 1,685.3 1,894.5 1,967.0 2,184.0 2,217.1 2,132.8 Other Income 10.4 16.0 24.3 32.0 25.6 30.1 Total Income 1,695.7 1,910.5 1,991.3 2,216.0 2,242.7 2,162.9 Total Expenses 1,275.7 1,320.6 1,375.2 1,927.6 1,990
Slide 10: Standalone Balance Sheet - Building assets
Standalone Balance Sheet - Building assets Balance Sheet (₹ Cr) FY19 FY20 FY21 FY22 FY23 FY24 Shareholders' Funds 474.3 813.5 1260.4 1390.3 1506.6 1611.3 Long-term Debt 284.0 56.0 0.0 0.0 0.0 0.0 Total Non-current Liabilities 20.8 79.7 59.1 56.6 58.1 72.9 Total Current Liabilities 162.8 220.6 290.6
Slide 11: Standalone Cash Flow Statement
Standalone Cash Flow Statement Particulars (₹ Cr) FY19 FY20 FY21 FY22 FY23 FY24 Profit before tax 336.2 533.2 571.4 222.8 189.5 182.6 Adjustments for: Non Cash Items / Other 82.4 51.9 27.2 33.1 44.4 60.1 Investment or Financial Items Operating profit before working capital changes 418.5 585.2 598.5
Slide 12: 5-years Performance
5-years Performance Operational Revenue (₹ Cr) EBITDA (₹ Cr) and EBITDA Margin (%) PAT (₹ Cr) and PAT Margin (%) 2,216 2,243 2,163 30.9% 30.9% 22.3% 1,911 1,991 1,696 24.8% 18.9% 11.2% 14.0% 13.0% 12.1% 7.5% 6.3% 6.2% 420 590 616 288 252 262 237 361 445 166 140 135 FY19 FY20 FY21 FY22 FY23 FY24 FY19
Slide 13: Diversified revenue base
Diversified revenue base FY19 FY24 Q1 FY25 568, 34% 865, 41% 206, 41% 431, 20% 95, 19% 128, 7% 989, 59% 837, 39% 201, 40% Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's 13 * Amt in ₹ crore
Slide 14: Company Overview
COMPANY OVERVIEW
Slide 15: The Journey
The Journey ▪ 2009 - Commencement of ▪ 1996 - Commencement of ▪ 2015 - USFDA, EIR for ▪ Paracetamol capacity IBB, MCA and Acetyl Ethyl Acetate Plant Ibuprofen ▪ 2019 - Unit-06 for has been increased to Chloride Plants ▪ 1999 - Commencement of ▪ 2016 - Unit-03 for new Pantoprazole (Dedicated) 3,600 T
Slide 16: Core management team
Core management team Varinder Gupta (Managing Director) ▪ Wide and rich experience of more than 35 years in the chemical & fertilizer industry and along Vikas Gupta with a comprehensive approach and strong (Joint Managing Director) Pharma API industry oversight has paved a way ▪ Academically equippe
Slide 17: Board of Directors
Board of Directors Rajender Mohan Malla (Chairman and Independent Director) ▪ With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs Harpal Singh ▪ In his most recent executive roles, he was MD & (Independent Director) CEO of PTC I
Slide 18: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility EUGMP Certification in Certified Halal in ISO 9001:2015, since 2015, recertified in Certificate of Suitability Certificate of DMF 2013, 2017 & accordance with Shariah 14001:2015 & 2019 from EDQM Registration From MFDS Recertification in 2020
Slide 19: Business Overview
BUSINESS OVERVIEW
Slide 20: Pharmaceuticals – Building API portfolio
Pharmaceuticals – Building API portfolio IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen having a capacity of 12000+ MT • Dedicated USFDA approved facilities for Ib
Slide 21: Specialty chemicals – capitalizing on global demand
Specialty chemicals – capitalizing on global demand IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 TPA Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 TPA • Strengthen
Slide 22: Manufacturing facilities
Manufacturing facilities API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC 1 3 5 intermediates & Specialty chemicals in Dedicated and multiproduct blocks system, PSA Nitrogen & Purified water continuous product delivery manner involved in manufacturing of APIs along with
Slide 23: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives Environment • State of the art Zero liquid Discharge (ZLD) Facility • Committed to ensure that our operations have minimal 100% Water impact on the environment neutral • Constantly monitoring environmental footprints and implementing relevant i
Slide 24: Industry Overview
INDUSTRY OVERVIEW
Slide 25: Pharmaceuticals – Emerging strongly out of pandemic
Pharmaceuticals – Emerging strongly out of pandemic Indian API Market World Pharmaceutical Industry • The Indian API market is expected to grow at a CAGR of 13.7% over the four years • India hosts 500 API manufacturers, contributing approximately 8% to the global API Industry. $1.6 8-10% $2.4 Trilli
Slide 26: Specialty Chemicals – an era of sustained robust growth
Specialty Chemicals – an era of sustained robust growth Short-term growth to remain subdued… • Demand headwinds from export markets, China’s rising supplies and inventory destocking have impacted margins & profitability of Indian players • Expectations of sluggish global growth, oversupplied industr
Slide 27: Way Forward
WAY FORWARD
Slide 28: Charting a path to success
Charting a path to success Four pronged strategy for growth Focus on Capacity Improved Expanding Regulated expansion in asset Non-Ibuprofen Markets Pharma & utilization Business Chemicals Increased contribution Added more than 10 The Company’s turnover The share of regulated products since 2017 in o
Slide 29: Expanding the non-Ibuprofen business
Expanding the non-Ibuprofen business (Analgesic and Antipyretic drugs) Multi Product facility focused on Paracetamol, with an Regulatory Filings: CEP installed capacity of approved; US DMF filed 3,600 MT/Annum, with a backward integration process (Antiplatelet drug, used in cardiovascular (Anticonsu
Slide 30: Thank You
Thank You Company : Investor Relations Advisors : IOL Chemicals and Adfactorspr Pvt. Ltd. Pharmaceuticals Ltd. Mr. Pardeep Kumar Khanna, Darshan Mankad CFO darshan.mankad@adfactorspr.com pardeepkhanna@iolcp.com Hanishi Shah hanishi.shah@adfactorspr.com www.iolcp.com www.adfactorspr.com
IOL Chemicals and Pharmaceuticals — Q1 FY2025 Earnings Presentation on 6ix